Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vascn.2004.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of Anti-Apoptotic Effects and Mechanisms of Astragaloside IV in a Rat Model of Cerebral Ischemia-Reperfusion Injury.
CNS Neurosci Ther
January 2025
Qingshan Lake Science and Technology Innovation Center, Hangzhou Medical College, Hangzhou, China.
Background: Ischemic stroke is a prevalent and life-threatening cerebrovascular disease that is challenging to treat and associated with a poor prognosis. Astragaloside IV (AS-IV), a primary bioactive component of Astragali radix, has demonstrated neuroprotective benefits in previous studies. This study aimed to explore the mechanisms through which AS-IV may treat cerebral ischemia-reperfusion injury (CIRI).
View Article and Find Full Text PDFEfficacy and Safety of Silodosin for the Treatment of Female LUTS: A 12-Week Prospective, Single-Center Study.
Low Urin Tract Symptoms
January 2025
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Objectives: This study aimed to evaluate the clinical efficacy and safety of silodosin in female patients with lower urinary tract symptoms (LUTSs), addressing the limited evidence supporting alpha-blocker use in this population.
Methods: A 12-week, single-arm, prospective, open-label study was conducted from May 2021 to January 2023. Female patients aged over 18 with an International Prostate Symptom Score (IPSS) ≥ 8 were enrolled and treated with silodosin (8 mg once daily).
Efficacy and Safety Analysis of Axitinib Combined with Sintilimab as Second-Line Treatment for Advanced Renal Cell Carcinoma: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Emergency Surgery, Qingdao Eighth People's Hospital, 266000 Qingdao, Shandong, China.
Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.
Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.
Substance Use and Concurrent Disorders: Current Context and the Need for Treatment Integration.
Can J Psychiatry
January 2025
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Medical device-related pressure injuries (MDRPIs) pose a significant risk in the home health environment, where patients may lack continuous professional oversight. Devices commonly used in the home environment with the potential to cause a MDRPI include but are not limited to nasogastric tubes, feeding tubes, nasal cannulas, nasal cannula prongs, airway pressure masks, indwelling urinary catheters, sequential compression devices, dressings, bandages, and tracheostomies. When a medical device is used for an extended period, it can lead to unrelieved pressure or edema, cause friction and/or shearing that impairs sensation, reduces circulation, and alters the microclimate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!